Burn-associated lipid-protein complex (LPC)

The burn-associated lipid-protein complex (LPC), frequently termed burn toxin, is a high-molecular-weight pathogenic entity produced in the skin following severe thermal injury (Schoenenberger GA, et al., 1972). It is formed through the heat-induced polymerization of cutaneous cell membrane components, resulting in a complex that possesses significant systemic toxicity. Upon entering the bloodstream, the LPC acts as a potent immunosuppressant and a trigger for the systemic inflammatory response syndrome (SIRS), often leading to multi-organ failure and increased susceptibility to sepsis (Allgöwer M, et al., 1973). Therapeutic strategies targeting the LPC include the use of cerium nitrate, which chemically fixes the toxin within the burn eschar to prevent its translocation into the circulation (Wassermann D, et al., 1989). Additionally, experimental research has explored the use of specific anti-LPC antibodies to neutralize the complex and mitigate its deleterious effects on the immune system. Understanding the role of this toxin is crucial for managing the systemic complications of major burns and improving patient survival rates in intensive care settings.

Other names

Burn toxinCutaneous burn toxinThermal-injury-derived toxinSchoenenberger toxinToxic lipid-protein complex

Chemical fixation of the toxin within the burn eschar to prevent systemic absorption, or direct neutralization via specific antibodies to mitigate immunosuppression and systemic inflammation.